LRMR
Larimar Therapeutics Inc

4,514
Mkt Cap
$267.9M
Volume
1.62M
52W High
$5.37
52W Low
$1.61
PE Ratio
-1.62
LRMR Fundamentals
Price
$3.13
Prev Close
$3.26
Open
$3.27
50D MA
$3.58
Beta
1.45
Avg. Volume
1.29M
EPS (Annual)
-$1.32
P/B
1.93
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten ratings firms that are covering the firm, Marketbeat.com reports...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Larimar Therapeutics (NASDAQ:LRMR) Raised to "Strong-Buy" at Leerink Partnrs
Leerink Partnrs raised Larimar Therapeutics to a "strong-buy" rating in a research note on Monday...
MarketBeat·13d ago
News Placeholder
Short Interest in Larimar Therapeutics, Inc. (NASDAQ:LRMR) Decreases By 19.2%
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 7,922,334...
MarketBeat·19d ago
News Placeholder
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Moderate Buy" by Analysts
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat.com...
MarketBeat·28d ago
News Placeholder
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the company, MarketBeat...
MarketBeat·2mo ago
News Placeholder
FY2025 Earnings Forecast for LRMR Issued By Leerink Partnrs
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Larimar Therapeutics in a report issued on...
MarketBeat·2mo ago
News Placeholder
Equities Analysts Issue Forecasts for LRMR FY2025 Earnings
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at Wedbush cut their FY2025 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research report...
MarketBeat·2mo ago
News Placeholder
William Blair Has Negative Forecast for LRMR FY2025 Earnings
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at William Blair cut their FY2025 earnings per share (EPS) estimates for Larimar Therapeutics in a research report...
MarketBeat·2mo ago
News Placeholder
FY2029 EPS Estimates for Larimar Therapeutics Cut by Wedbush
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Stock analysts at Wedbush dropped their FY2029 earnings estimates for shares of Larimar Therapeutics in a note issued to investors on...
MarketBeat·2mo ago
News Placeholder
Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Misses Estimates By $0.22 EPS
Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·2mo ago
<
1
2
...
>

Latest LRMR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.